Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Clinical Nuclear Medicine|May 13, 2025
PSMA Radioligand Therapy in Advanced Age: Insights From an 85y+ mCRPC Patient CohortMoritz B Bastian, Benedikt Wörl, Arne Blickle, et al.
EJNMMI Research|July 6, 2025
Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopeniaMoritz B Bastian, Tilman Speicher, Arne Blickle, et al.
Cancers|January 20, 2021
18F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with LenvatinibFreba Ahmaddy, Caroline Burgard, Leonie Beyer, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|October 7, 2024
Outstanding increase in tumor-to-background ratio over time allows tumor localization by [89Zr]Zr-PSMA-617 PET/CT in early biochemical recurrence of prostate cancerCaroline Burgard, Florian Rosar, Elena Larsen, et al.
Cancers|November 13, 2021
Course of Disease and Clinical Management of Patients with Poorly Differentiated Thyroid CarcinomaFreba Grawe, Atika Cahya, Matthias P Fabritius, et al.
Cancers|October 26, 2024
Analysis of Molecular Imaging Biomarkers Derived from [18F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [225Ac]Ac-PSMA-617-Augmented [177Lu]Lu-PSMA-617 Radioligand TherapyCaroline Burgard, Fadi Khreish, Lukas Dahlmanns, et al.
Clinical Nuclear Medicine|May 4, 2026
Outcome and Safety of Radioligand Therapy With [161Tb]Tb-PSMA-617 After Re-Progression in mCRPC Patients Previously Treated With [177Lu]Lu-PSMA-617Florian Rosar, Caroline Burgard, Sophia Phuong Thao Hoang, et al.
Molecular Pharmaceutics|November 18, 2023
Radiometal Complexes as Pharmacokinetic Modifiers: A Potent 68Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonist Based on the Macrocyclic Metal Chelator NODIA-MeMoritz-Valentin Schreck, Caroline Burgard, Alexander Schmidtke, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 30, 2025
PSMA PET/CT in biochemical recurrence of prostate cancer with PSA levels ≤ 0.2 ng/mL: a German multicenter analysis of conventional PSMA tracers, including [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA I&T, and [18F]PSMA-1007Caroline Burgard, Madita Frei, Arne Blickle, et al.
Clinical Nuclear Medicine|January 9, 2025
225 Ac-PSMA-617 Augmentation After Insufficient Response Under 177 Lu-PSMA-617 Radioligand Therapy in mCRPC: Evaluation of Outcome and Safety From a Prospective Registry (REALITY Study)Florian Rosar, Fadi Khreish, Lea Sophie Nagel, et al.
Pageof 7